Cargando…

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women

To assess and compare the gynaecological consequences of the use of 2 antioestrogens we examined 167 postmenopausal breast cancer patients before and during the use of either tamoxifen (20 mg/day, n = 84) or toremifene (40 mg/day, n = 83) as an adjuvant treatment of stage II–III breast cancer. Detai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marttunen, M B, Cacciatore, B, Hietanen, P, Pyrhönen, S, Tiitinen, A, Wahlström, T, Ylikorkala, O
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363827/ https://www.ncbi.nlm.nih.gov/pubmed/11286468 http://dx.doi.org/10.1054/bjoc.2001.1703

Ejemplares similares

The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer
por: Saarto, T, et al.
Publicado: (2001)

Influence of the antioestrogen tamoxifen on normal breast tissue.
por: Walker, K. J., et al.
Publicado: (1991)

K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene
por: Hachisuga, T, et al.
Publicado: (2005)

Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer
por: Song, Dandan, et al.
Publicado: (2021)

Non-Steroidal Antioestrogens
por: Barnes, D.
Publicado: (1983)

Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
por: PyrhÃ¶nen, S., et al.
Publicado: (1997)

A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis
por: Hong, Jin, et al.
Publicado: (2020)

Circumvention of Daunorubicin Resistance by a New Tamoxifen Derivative, Toremifene, in Multidrug‐resistant Cell Line
por: Urasaki, Yoshimasa, et al.
Publicado: (1994)

Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7.
por: Lykkesfeldt, A. E., et al.
Publicado: (1984)

Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis
por: He, Tao, et al.
Publicado: (2020)

Toremifene interacts with and destabilizes the Ebola virus glycoprotein
por: Zhao, Yuguang, et al.
Publicado: (2016)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Preventive effects of antioestrogen on mammary and pituitary tumorigenesis in rats.
por: Sumi, C., et al.
Publicado: (1984)

Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen
por: Wang, Hongyue, et al.
Publicado: (2021)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Human desmoid fibroblasts: matrix metalloproteinases, their inhibitors and modulation by Toremifene
por: Balducci, Chiara, et al.
Publicado: (2005)

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
por: Wong, Z-W, et al.
Publicado: (2004)

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004)

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
por: Godinho, M F E, et al.
Publicado: (2012)

A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study
por: Gu, Ran, et al.
Publicado: (2012)

High-Dose Toremifene for Fulvestrant-Resistant Metastatic Breast Cancer: A Report of Two Cases
por: Mori, Ryutaro, et al.
Publicado: (2014)

Tamoxifen inhibits the biosynthesis of inositolphosphorylceramide in Leishmania
por: Trinconi, Cristiana T., et al.
Publicado: (2018)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Optimism predicts sustained vigorous physical activity in postmenopausal women()
por: Progovac, Ana M., et al.
Publicado: (2017)

Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer
por: Torrisi, R, et al.
Publicado: (2001)

Development and characterization of a tamoxifen-resistant breast carcinoma xenograft
por: Naundorf, H, et al.
Publicado: (2000)

Comparative Study on Hysteroscopic and Histologic Examinations of the Endometrium in Postmenopausal Women Taking Tamoxifen
por: Jung, Hyuk, et al.
Publicado: (2018)

Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study
por: Shien, Tadahiko, et al.
Publicado: (2017)

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy
por: Goldstein, S. R., et al.
Publicado: (2014)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
por: Gjerde, Jennifer, et al.
Publicado: (2010)

Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women
por: Daidone, M G, et al.
Publicado: (2000)

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2013)

First do no harm: extending the debate on the provision of preventive tamoxifen
por: Will, B P, et al.
Publicado: (2001)

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
por: Saarto, T., et al.
Publicado: (1997)

In Vitro Effects of Oestrogens, Antioestrogens and SERMs on Pancreatic Solid Pseudopapillary Neoplasm-Derived Primary Cell Culture
por: Tognarini, Isabella, et al.
Publicado: (2010)

Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women
por: Balleine, R L, et al.
Publicado: (1999)

Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study
por: Zeleniuch-Jacquotte, A, et al.
Publicado: (2001)

Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer
por: Lee Meeuw Kjoe, Philippe R, et al.
Publicado: (2023)

Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
por: Sharp, S. Y., et al.
Publicado: (1994)

Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor
por: Bensmail, A, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_srjeb59085rfei6r150st7t5nj